Month: August 2016

Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference

CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company’s President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference …

Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference Read More »

Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder

CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient visits in the Company’s reconnect studies, consisting of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexual desire disorder (HSDD), have been completed. “We are very excited with the completion of …

Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder Read More »

Palatin Technologies Announces Closing of $9.2 Million Financing

CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that today it closed on a previously disclosed underwritten offering of units with gross proceeds of $9,225,000.  Canaccord Genuity Inc. acted …

Palatin Technologies Announces Closing of $9.2 Million Financing Read More »

Palatin Technologies Announces $9.25 Million Financing

CRANBURY, N.J., Aug. 1, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has priced an underwritten offering of units with anticipated gross proceeds of $9.25 million.  Each unit will consist of a share of common stock and a Series H warrant to purchase 0.75 of a share of common stock.  Investors …

Palatin Technologies Announces $9.25 Million Financing Read More »

Scroll to Top